October 12, 2019 09:38 AM EDT

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year

John Carroll

Editor & Founder

In a rare twist for Eli Lilly’s historically slow-moving R&D group, the pharma giant has seized bragging rights to a first-in-class new drug approval. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year